CEL-SCI (id:194 CVM)
3.00 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/23/2024 7:20:16 PM)
Exchange closed, opens in 14 hours 9 minutes
About CEL-SCI
Market Capitalization 48.82M
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Headquarters (address) |
8229 Boone Boulevard Vienna 22182 VA United States |
Phone | 703 506 9460 |
Website | https://cel-sci.com |
Employees | 0 |
Sector | Healthcare |
Industry | Biotechnology |
Ticker | CVM |
Exchange | New York Stock Exchange |
Currency | USD |
52 week range | 3.00 - 3.23 |
Market Capitalization | 48.82M |
Dividend yield forward | 136.99 % |
Dividend yield forward United States (ID:6, base:1858) | 4.48 % |
P/E trailing | -1.00 |
P/E forward | -1.74 |
Price/Book | 4.90 |
Beta | 3.00 |
EPS | 3.00 |
EPS United States (ID:6, base:3382) | 24.33 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: CEL-SCI has raised their dividend 136.99 years in a row. This is below the 42121.954600 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: CEL-SCI has raised their dividend 136.99 years in a row. This is below the 42121.954600 year average in the 'Biotechnology' industry